- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00879216
VA106483 and Alpha Blocker Interaction Study in Elderly Males
A Single Centre, Double-blind, Placebo Controlled Crossover Study in Elderly Male Subjects to Investigate the Plarmacodynamic Interaction of VA106483 Administered Concomitanctly With Alpha-blocker Therapy
Study Overview
Detailed Description
VA106483 is intended to be used as a treatment for patients suffering from nocturia (defined as waking to urinate at least once per night between periods of sleep). Nocturia is a condition that often worsens as sufferers get older. This may be due to an over-active bladder muscle, the bladder being able to hold less urine at night-time or over production of urine in the bladder at night. Some of the treatments available for nocturia have side-effects which make them unsuitable for elderly patients. These side-effects have not been seen in studies with VA106483, which makes it potentially suitable for treating elderly patients.
Nocturia is commonly associated with Benign Prostatic Hypertrophy (or BPH, a non-cancerous enlargement of the prostate gland, which often results in problems passing water). Of the patients who suffer from BPH, an estimated 40-85% experience the symptoms of waking at night to pass water.
Treatments which are commonly prescribed for BPH include alpha-blockers which work by improving urine flow by a muscle relaxant effect. Alpha-blockers are known to cause hypotension (lowering of blood pressure which can cause dizziness in some patients) . Since it is likely that subjects may be co-prescribed VA106483 and alpha-blockers, the purpose of this study is to determine that giving VA106483 does not increase the hypotensive effects of alpha-blockers
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
-
Edinburgh, United Kingdom, EH12 1DF
- Charles River Clinical Services
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Male aged 65 years of age and above
- No clinically important abnormal physical, laboratory or vital sign findings in the opinion of the Investigator
- Provision of written informed consent to participate
- No recent alpha-blocker therapy
- Not taking any concomitant medication known to be a cytochrome 3A4 inhibitor
- Not taking any prescribed or over the counter medications unless agreed with the Investigator and Sponsor
- No evidence of serious pathology or disease including poorly controlled endocrine disorders; active liver or biliary disease or severe kidney problems; syndrome of inappropriate antidiuretic hormone secretion
- No history of orthostatic hypotension or syncope.
- No known hypersensitivity to the IMP or alpha blocker, including severe lactose intolerance.
- No history of drug or alcohol abuse
- Negative for HIV, hepatitis B or C
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Sugar pill
|
4 mg orally on either Day 7 or 10 with the placebo crossover treatment on the alternate day.
|
Experimental: VA106483
|
4 mg orally on either Day 7 or 10 with the placebo crossover treatment on the alternate day.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Blood pressure, Heart rate
Time Frame: For 8 hours after dosing
|
For 8 hours after dosing
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Medical Director, Charles River Clinical Services, Edinburgh, UK
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 483-003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nocturia
-
Winthrop University HospitalCompleted
-
Sanwa Kagaku Kenkyusho Co., Ltd.CompletedNocturia Due to Nocturnal PolyuriaJapan
-
Ferring PharmaceuticalsCompletedNocturia Associated With Nocturnal PolyuriaGermany
-
Wellesley Pharmaceuticals, LLCCompleted
-
Ferring PharmaceuticalsCompletedNocturiaUnited States
-
Corporacion Parc TauliCompleted
-
Ferring PharmaceuticalsCompleted
-
Cognitive Research CorporationNovartis PharmaceuticalsWithdrawn
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States